iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroidLikeFollowShareRead full articlehttps://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fj.201802307RShare your feedbackQuestions (0)Post questionYour question will be sent privately to Cynata Therapeutics. The company may choose to make this question public.Start the conversationAsk Cynata Therapeutics a question about this update.DiscoverShare your feedbackDiscover
